Drug intelligence / Profile preview

dengue tetravalent vaccine (live, attenuated)

Development stage: Approved
Lead developer: Sanofi Pasteur
Modality: Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

Dengvaxia (CYD-TDV) is a live-attenuated tetravalent vaccine developed by Sanofi Pasteur for the prevention of dengue fever caused by dengue virus serotypes 1, 2, 3, and 4. It is constructed using the ChimeriVax technology, which utilizes the yellow fever 17D vaccine virus as a genetic backbone. The genes encoding the pre-membrane (prM) and envelope (E) proteins of the yellow fever virus are replaced with those from the four dengue virus serotypes. This chimeric approach allows the vaccine to induce neutralizing antibodies against all four dengue serotypes while maintaining the attenuation profile of the yellow fever 17D strain. It is primarily indicated for individuals aged 6 to 45 years (depending on the region) living in endemic areas who have had a laboratory-confirmed previous dengue infection, as it can increase the risk of severe dengue in seronegative individuals.

Brand names: Dengvaxia
Other names: ChimeriVax-DengueChimeriVax Dengue Tetravalent VaccineCYD dengue virus serotype 1 live (attenuated) antigenCYD dengue virus serotype 2 live (attenuated) antigenCYD dengue virus serotype 3 live (attenuated) antigenCYD dengue virus serotype 4 live (attenuated) antigen

Beyond the preview

Go deeper on dengue tetravalent vaccine (live, attenuated).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on dengue tetravalent vaccine (live, attenuated).

Explore the full profile